Showing results (531-540 of 578) with videos related to

Sort By:
Pageof 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2019
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 TrialR Wendel Naumann, Antoine Hollebecque, Tim Meyer, et al.
Nature Communications|August 18, 2018
The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent mannerMette Ø Agerbæk, Sara R Bang-Christensen, Ming-Hsin Yang, et al.
The Lancet. Oncology|October 28, 2017
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trialPiero Ferolla, Maria Pia Brizzi, Tim Meyer, et al.
ESMO Open|August 28, 2020
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trialRobin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, et al.
British Journal of Sports Medicine|May 27, 2022
International Olympic Committee (IOC) consensus statement on acute respiratory illness in athletes part 2: non-infective acute respiratory illnessMartin Schwellnus, Paolo Emilio Adami, Valerie Bougault, et al.
British Journal of Sports Medicine|July 21, 2022
International Olympic Committee (IOC) consensus statement on acute respiratory illness in athletes part 1: acute respiratory infectionsMartin Schwellnus, Paolo Emilio Adami, Valerie Bougault, et al.
The Lancet. Oncology|April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trialAna Oaknin, Kathleen Moore, Tim Meyer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2019
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenibTim A Labeur, Sarah Berhane, Julien Edeline, et al.
Lancet (London, England)|April 25, 2017
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialAnthony B El-Khoueiry, Bruno Sangro, Thomas Yau, et al.
Frontiers in Immunology|April 1, 2022
SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral ImmunitySophie Steiner, Tatjana Schwarz, Victor M Corman, et al.
Pageof 58